

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08a (08-03)  
Approved for use through 07/31/2008. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/067,892	
			Filing Date	2/8/2002	
			First Named Inventor	McCormick et al.	
			Art Unit	1642	
			Examiner Name	Christopher H. YAEN	
Sheet	1	of	1	Attorney Docket Number	42256

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
PET		US-6,403,371	06/11/2002	CONRAD et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PKT		SHU, et al., "Secretion of a single-gene-encoded immunoglobulin from myeloma cells", Proc. Natl. Acad. Sci. USA (1993) 90:7995-7999	

Examiner Signature	P.E. O'F.	Date Considered	6/23/05
-----------------------	-----------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO			<div style="text-align: center;">  </div>		
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/067,892	
			Filing Date	2/8/2002	
			First Named Inventor	McCormick et al.	
			Art Unit	1642	
Examiner Name	Yaen, Christopher H.				
Sheet	1	of	2	Attorney Docket Number	42256

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
PET		WO 94/08008	4/14/1994	HAWKINS, et al.		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
PET		BENVENUTI and BURRONE, "Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V <sub>L</sub> /V <sub>H</sub> determinants", <i>Gene Therapy</i> (2001) 8:1555-1561			
PET		CASPAR, et al., "Idiotypic vaccines for non-hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idotypes: comparison of different vaccine formulations", <i>Blood</i> (1997) 90(9):3699-3706			
PET		DE GRUIJL and CUREL, "Cancer vaccine strategies get bigger and better", <i>Nature Medicine</i> (1999) 5(10):1124-1125			
PET		DONNELLY, "Cancer vaccine targets leukemia", <i>Nature Medicine</i> (2003) 9(11):1354-1356			
PET		EVANS and KAYE, "Vaccine therapy for cancer - fact or fiction?" <i>Q J Med.</i> (1999) 92:299-307			
PET		FITCHEN, et al., "Plant virus expressing hybrid coat protein with added murine epitope elicits autoantibody response", <i>Vaccine</i> (1995) 13:1051-1057			
PET		GIRARD, et al., "Methodes d'etudes des virus", <i>Virologie Moleculaire</i> (1989), Chapter 2, pp. 61-65			
PET		HAKIM, et al., "A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines", <i>J. Immun.</i> (1996) 157(12):5503-5511			
PET		HENNECKE, et al., "Non-repetitive single-chain Fv linkers selected by selectively infective phage (SIP) technology", <i>Protein Engineering</i> (1998) 11(5):405-410			
PET		HSU, et al., "Tumor-Specific idotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial", <i>Blood</i> (1997) 89(9):3129-3135			
PET		JERALA, et al., "Improved expression and evaluation of polyethyleneimine precipitation in isolation of recombinant cysteine proteinase inhibitor Stefin B", <i>Protein Expression and Purification</i> (1994) 5:65-69			

Examiner Signature		Date Considered	6/23/05
--------------------	---	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/067,892
				Filing Date	2/8/2002
				First Named Inventor	McCormick et al.
				Art Unit	1642
				Examiner Name	Yaen, Christopher H.
Sheet	2	of	2	Attorney Docket Number	42256

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PKT		KING, et al., "DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma", <i>Nature Medicine</i> (1998) 4(11):1281-1286	
PKT		LANGEVELD, et al., "Effective induction of neutralizing antibodies with the amino terminus of VP2 of canine parvovirus as a synthetic peptide", <i>Vaccine</i> (1994) 12:1473-1480	
PKT		STEMMER, et al., "Selection of an active single chain Fv antibody from a protein linker library prepared by enzymatic inverse PCR", <i>Biotech.</i> (1993) 14(2):256-265	
PKT		TANG, et al., "Selection of linkers for a catalytic single-chain antibody using phage display technology" (1996) 271(26):15682-15686	
PKT		TAVLADORAKI, et al., "A single-chain antibody fragment is functionally expressed in the cytoplasm of both <i>Escherichia coli</i> and transgenic plants", <i>European J. Biochem.</i> (1999) 262(2):617-624	
PKT		TURNER, et al., "Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology", <i>J. Immun. Methods</i> (1997) 205(1):43-54	

Examiner Signature	<i>P.C. [Signature]</i>	Date Considered	6/23/05
--------------------	-------------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)  Sheet 1 of 1			<b>Complete if Known</b>	
			Application Number	10/067,892
			Filing Date	2/8/2002
			First Named Inventor	McCormick et al.
			Art Unit	1642
			Examiner Name	YAEN, Christopher H.
			Attorney Docket Number	42256

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PPT		FIEDLER, et al., "Optimization of scFv antibody production in transgenic plants", <i>Immunotechnology</i> (1997), 3:205-216	
PPT		VAQUERO, et al., "Transient expression of a tumor-specific single-chain fragment and a chimeric antibody in tobacco leaves", <i>Proc. Natl. Acad. Sci.</i> (1999), 96:11128-11133	

Examiner Signature		Date Considered	6/28/05
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Form PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 42256	SERIAL NO. Div of 09/522,900
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT McCormick et al.	
		FILING DATE 8 February 2002	GROUP TBA

U.S. PATENT DOCUMENTS												
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS
PKT		5	8	6	5	2	8	7	9 Feb 1999	Price et al.		
PKT		5	2	4	6	8	4	5	31 Aug 1993	Fujii, deceased et al.		
PKT		5	5	4	1	3	0	9	30 Jul 1996	Prasher		
PKT		4	7	5	6	0	2	5	26 Jul 1998	Estell et al.		
PKT		5	5	9	5	8	8	7	21 Jan 1997	Coolidge et al.		
PKT		5	6	5	6	4	5	6	12 Aug 1997	Stout et al.		
PKT		4	7	8	2	1	3	7	1 Nov 1988	Hopp et al.		
PKT		5	6	0	8	0	3	9	4 Mar 1997	Pastan		
PKT		5	9	3	9	4	5	5	17 Aug 1999	Rephaeli		
PKT		5	9	1	2	1	7	2	15 Jun 1999	Eshhar et al.		
PKT		5	9	0	6	9	3	6	25 May 1999	Eshhar et al.		
PKT		5	8	8	5	7	9	3	23 Mar 1999	Griffiths et al.		
PKT		5	7	9	2	6	0	4	11 Aug 1998	Jefferies et al.		

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

PKT	Pharmaceutical Biotechnology, "Vaccine Design: The Subunit and Adjuvant Approach." Powell & Newman, Eds. Vol. 6 pp. 389-412, (1995).
PKT	Proc. Natl. Acad. Sci. USA, McCormick et al., "Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants." Vol. 96, pp. 703-708, (1999).

EXAMINER

P. C. P. J.

DATE CONSIDERED

6/28/05

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609;  
Draw Line through citation if not in conformance and not considered. Include copy of this form with  
next communication to applicant.

10/067892  
10/067892  
02/09/02

Form PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 42256		SERIAL NO. Div of 09/522,900						
INFORMATION DISCLOSURE CITATION  (Use several sheets if necessary)				APPLICANT McCormick et al.		GROUP TBA						
				FILING DATE 8 February 2002								
U.S. PATENT DOCUMENTS												
EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
PKT	5	6	5	8	7	5	3	19 Aug 1997	Paul, et al.			
PKT	5	6	4	8	2	1	9	15 Jul 1997	MacKay et al.			
PKT	5	5	9	9	5	3	8	4 Feb 1997	Paul et al.			
PKT	5	6	3	7	4	5	4	16 Jun 1997	Harley			
PKT	5	5	3	8	8	5	4	23 Jul 1996	Faustman			
PKT	5	2	3	6	8	3	6	17 Aug 1993	Paul			
PKT	5	2	2	9	2	7	2	20 Jul 1993	Paul et al.			
PKT	5	1	3	5	9	1	5	4 Aug 1992	Czarniecki et al.			
PKT	4	3	8	8	4	4	1	14 Jun 1983	Katz			
PKT	4	1	9	1	6	6	8	4 Mar 1980	Katz			
PKT	4	2	2	2	9	0	7	16 Sep 1980	Katz			
PKT	5	6	0	2	0	1	5	11 Feb 1997	Sudhir			
PKT	5	6	9	0	9	3	3	25 Nov 1997	Cobbold et al.			
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)												
										DATE CONSIDERED 6/23/05		
EXAMINER P.B. [Signature]												
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.												